# Shanghai Fosun Pharmaceutical trials: 36

ClinicalTrials.gov lists 36 trials with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. as lead sponsor, 18 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.: 36 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/shanghai-fosun-pharmaceutical-industrial-development-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 36
- Recruiting or not yet: 18
- Read on: November 19, 2026

## Trials

The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933666 | A Phase I of FXS0260 in Advanced Solid Tumor | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Not yet recruiting | Solid Tumor Refractory to Conventional Treatment | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933666) |
| November 4, 2026 | NCT07914894 | A Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients. | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 3 | Not yet recruiting | Paroxysmal Nocturnal Hemoglobinuria | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914894) |
| October 13, 2026 | NCT07872579 | Mass Balance Study of \[¹⁴C\]FXS4640 in Healthy Adult Males | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Not yet recruiting | Healthy Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872579) |
| September 25, 2026 | NCT07840820 | Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 2/3 | Not yet recruiting | Non-segmental Vitiligo | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840820) |
| August 6, 2026 | NCT07750665 | FXS6837 for the Treatment for IgAN Patients（Longterm Study） | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 2 | Not yet recruiting | Primary IgAN | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750665) |
| August 5, 2026 | NCT07747090 | A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH. | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 3 | Not yet recruiting | Paroxysmal Nocturnal Hemoglobinuria | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747090) |
| July 10, 2026 | NCT07695779 | QT Interval Effects Study of Oral FXS5626 Tablets | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Recruiting | Evaluation of QTc Interval | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07695779) |
| June 18, 2026 | NCT07657052 | A Multicenter, Open-label Study Evaluating the Long-term Safety and Efficacy of XH-S003 Capsules in Patients With Paroxysmal Nocturnal... | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Not applicable | Enrolling by invitation | Paroxysmal Nocturnal Hemoglobinuria | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657052) |
| June 9, 2026 | NCT07634744 | A Phase IIa Study in Primary IgA Nephropathy Patients | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 2 | Completed | IgA Nephropathy | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634744) |
| May 29, 2026 | NCT07616089 | Phase I Study of FXS0683 in the Treatment of Blood Tumors | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Recruiting | B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616089) |
| May 1, 2026 | NCT07562581 | A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 2 | Recruiting | Non-small Cell Lung Caner, KRAS-mutated, Metastasis, Previous Treamted | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07562581) |
| April 30, 2026 | NCT07558200 | Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Not yet recruiting | Solid Tumors, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07558200) |
| April 27, 2026 | NCT07552012 | A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 2 | Recruiting | Active Non-anterior, Non-infectious Uveitis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552012) |
| March 31, 2026 | NCT07502638 | FXS6837 for the Treatment of IgAN Patients | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 2 | Not yet recruiting | IgAN | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502638) |
| January 16, 2026 | NCT07345637 | Phase I Study of FXS887 in the Treatment of Solid Tumors | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Not yet recruiting | Solid Tumor Refractory to Conventional Treatment | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07345637) |
| June 25, 2025 | NCT07035652 | The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety... | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Active not recruiting | Chronic Obstructive Pulmonary Disease | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07035652) |
| June 17, 2025 | NCT07024394 | Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1/2 | Not yet recruiting | Neurofibromatosis 1, Plexiform Neurofibroma, NF1 | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024394) |
| June 4, 2025 | NCT07004075 | FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 3 | Not yet recruiting | Low-grade Glioma, Pediatric Low-grade Gliomas, pLGG With BRAF Alteration | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07004075) |
| May 20, 2025 | NCT06981091 | A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of... | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 2 | Active not recruiting | Non-Cystic Fibrosis Bronchiectasis | 234 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06981091) |
| May 18, 2025 | NCT06978699 | A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 2 | Completed | PNH - Paroxysmal Nocturnal Hemoglobinuria | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06978699) |
| April 20, 2025 | NCT06936527 | XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1/2 | Enrolling by invitation | Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06936527) |
| March 5, 2025 | NCT06858618 | FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 2 | Active not recruiting | Safety, Antitumor Activity, PK Profile | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06858618) |
| February 11, 2025 | NCT06820268 | A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Recruiting | B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06820268) |
| August 26, 2024 | NCT06569420 | Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 3 | Active not recruiting | Non-Small Cell Lung Cancer, ALK-positive, SAF-189s | 275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06569420) |
| August 1, 2024 | NCT06531486 | A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Recruiting | Solid Tumor, Ovarian Cancer, Breast Cancer, Endometrial Cancer, Osteosarcoma | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06531486) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 1/2 | 4 |
| Phase 2 | 9 |
| Phase 2/3 | 1 |
| Phase 3 | 6 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Not yet recruiting | 11 |
| Recruiting | 7 |
| Completed | 6 |
| Active not recruiting | 5 |
| Unknown | 3 |
| Enrolling by invitation | 2 |
| Suspended | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Leukemia, Myeloid, Acute | 4 |
| Hemoglobinuria, Paroxysmal | 4 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Breast Neoplasms | 3 |
| Neurofibromatosis 1 | 3 |
| Neurofibroma, Plexiform | 3 |
| Lymphoma, B-Cell | 2 |
| Myelodysplastic Syndromes | 2 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Melanoma | 1 |
| Carcinoma, Hepatocellular | 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |
| Ovarian Neoplasms | 1 |
| Endometrial Neoplasms | 1 |
| Osteosarcoma | 1 |
| Uveitis | 1 |
| Motor Activity | 1 |
| Bronchiectasis | 1 |
| Fibrosis | 1 |
| Neoplasm Metastasis | 1 |
| Glomerulonephritis, IGA | 1 |
| Colorectal Neoplasms | 1 |
| Histiocytosis, Langerhans-Cell | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Tax preparation firms in the United States](https://specstream.ai/data/businesses/tax-preparation-firms/united-states)
- [Kitchen remodelers in the United States](https://specstream.ai/data/businesses/kitchen-remodelers/united-states)
- [Caterers in the United States](https://specstream.ai/data/businesses/caterers/united-states)
- [Social security law firms in the United States](https://specstream.ai/data/businesses/social-security-law-firms/united-states)
- [Immunodermatology practices in the United States](https://specstream.ai/data/businesses/immunodermatology-practices/united-states)
